Contemporary Management of Patients with Systemic Lupus Erythematosus: A Case-based Approach

1.25 CME
1.25 AAPA
75 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Contemporary Management of Patients with Systemic Lupus Erythematosus: A Case-based Approach

Overview

Provider Statement

This continuing medical education activity is provided by Annenberg

Support Statement

This activity is supported by an educational grant from GSK.

Target Audience

This activity was developed for rheumatologists, nephrologists, rheumatology and nephrology advanced practice providers, nephropathologists, primary care physicians, emergency physicians, pharmacists, and other healthcare providers involved in the care of patients with systemic lupus erythematosus, including lupus nephritis.

Activity Description

This modular continuing education activity provides an update on the epidemiology, monitoring, and treatment of patients with systemic lupus erythematosus (SLE). Diane Kamen, MD, and Anca Askanase, MD, examine the current research on demographic groups with an increased risk of SLE and its severe complications, including lupus nephritis (LN). They also review the application of the most current treatment goals and classification criteria to speed diagnosis and guide disease activity monitoring. The expert faculty provide guidance on the integration of newly approved treatments into the EULAR treatment algorithms for SLE, and how these treatments can be used for patients with LN. Two case studies are utilized to illustrate the application of key concepts.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Explain the importance of prompt and accurate diagnosis of SLE and its consequences such as LN
  • Develop and apply validated measures of disease activity to inform SLE treatment decisions
  • Initiate evidence-based treatment consistent with current guidelines and approved indications to reduce disease progression and excessive use of corticosteroids
  • Discuss the impact of gender and ethnicity on prevalence and severity of SLE/LN
  • Develop a multidisciplinary team approach to diagnose and manage patients with SLE/LN

Faculty

Diane Kamen, MD
Associate Staff
Department of Allergy and Clinical Immunology
Cleveland Clinic
Cleveland, Ohio

Anca Askanase, MD
Professor of Pediatrics
NYU Grossman School of Medicine
New York, New York

Reviewers

Additional content planners
The following have no significant relationship to disclose:
Chris Fischer, MCs, MD (Medical Writer)
Eugene Cullen, MD (Peer Reviewer)
Amber Lea Lambert, MSN, FNP-C, DNP (Nurse Planner)

Accreditation

Jointly_Accredited_Provider_PNGIn support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Credit
The Annenberg Center designates this enduring material for a maximum 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PAPhysician Assistant Credit
The Annenberg Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until July 27, 2024. PAs should only claim credit commensurate with the extent of their participation.

Pharmacist Credit
The Annenberg Center designates this knowledge-based activity for a maximum of 1.25 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Nurse Credit
The Annenberg Center designates this education for a maximum of 1.25 American Nurses Credentialing Center (ANCC) contact hours, including 1.25 pharmacology hour.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.75 contact hour.  To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Credit Designation

1.25 ACCME
1.25 ANCC including 0.75 pharmacology hour.
1.25 CA-BRN
1.25 AAPA
1.25 ACPE

How to Participate in This Activity and Obtain CE Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

Disclosures

It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals with the potential to impact the content of an accredited education activity are expected to identify and reference off-label product use and disclose relationships with ACCME-defined ineligible companies.

The Annenberg Center assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant financial relationships that are identified are mitigated by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center for Health Sciences at Eisenhower disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Faculty reports the following relationship(s)

Anca D. Askanase, MD, MPH
Consultant: AstraZeneca, BMS, GSK

Data Safety Monitoring Board:  Amgen

Research Support: Eli Lilly, Idorsia, Janssen, Pfizer, UCB

Diane L. Kamen, MD
Data Safety Monitoring Board: Alpine Immune Sciences, Equillium

Reviewers report the following relationship(s)

Additional content planners
The following have no significant relationship to disclose:
Chris Fischer, MCs, MD (Medical Writer)
Eugene Cullen, MD (Peer Reviewer)
Amber Lea Lambert, MSN, FNP-C, DNP (Nurse Planner)

Annenberg Center for Health Sciences
All staff at the Annenberg Center have no relevant financial relationships to disclose.

All the relevant financial relationships listed for these individuals have been mitigated.

Unlabeled and Investigational Usage

The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.

Our Policy on Privacy

Annenberg Center respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at https://annenberg.net/pages/privacyPolicy.php

Contact Information

For help or questions about this activity please contact Continuing Education:
ce@annenberg.net